# Biosimilar PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/biosimilar

> Biosimilar, sponsored by Alvotech (ALVO), received a complete response letter from the FDA; the decision is dated Nov 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | biosimilar |
| Codes |  |
| Sponsor | Alvotech (ALVO) https://sec-api.dev/companies/alvo/catalysts |
| Indications | [neovascular](https://sec-api.dev/indications/neovascular), [with inflammatory conditions](https://sec-api.dev/indications/with-inflammatory-conditions), with neovascular, [osteoporosis in women](https://sec-api.dev/indications/osteoporosis-in-women), [eye disorders](https://sec-api.dev/indications/eye-disorders) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jul 2022: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-03-27, last confirmed 2025-03-27.
- SEC Form 10-K (accession 0001628280-25-015052): "In July 2022, we initiated the confirmatory clinical study for AVT06 and, in January 2024, we announced positive topline results from the confirmatory study." https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm

### August 2, 2022: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: neovascular.
- First seen 2025-03-17, last confirmed 2025-03-17.
- SEC Form 10-K (accession 0001558370-25-003126): "CIMERLI (ranibizumab-eqrn), a Lucentis biosimilar, was approved by the FDA on August 2, 2022 for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization and we launched CIMERLI commercially in the United States on October 3, 2022." https://www.sec.gov/Archives/edgar/data/1512762/000155837025003126/chrs-20241231x10k.htm

### Feb 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-03-27, last confirmed 2025-03-27.
- SEC Form 10-K (accession 0001628280-25-015052): "In February 2024, we received U.S. FDA approval for AVT02 as an interchangeable high-concentration citrate-free biosimilar to Humira, AVT02 also qualifies for exclusivity as a high-concentration biosimilar." https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm

### February 24, 2024: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-06-15, last confirmed 2026-06-16.
- SEC prospectus (424B) (accession 0000930413-26-001864): "2023, we announced that the FDA had accepted our resubmitted BLA with a February 24, 2024 Biosimilar User Fee Act (BsUFA) goal date." https://www.sec.gov/Archives/edgar/data/1898416/000093041326001864/c116682_424b5.htm
- SEC prospectus (424B) (accession 0000930413-26-001857): "2023, we announced that the FDA had accepted our resubmitted BLA with a February 24, 2024 Biosimilar User Fee Act (BsUFA) goal date." https://www.sec.gov/Archives/edgar/data/1898416/000093041326001857/c116682_424b5.htm

### Apr 2024: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-03-27, last confirmed 2025-03-27.
- SEC Form 10-K (accession 0001628280-25-015052): "•In April 2024, the Company announced positive topline results from a confirmatory clinical study for AVT05, a proposed biosimilar for Simponi and Simponi Aria." https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm
- SEC Form 10-K (accession 0001628280-25-015052): "•In April 2024, the Company announced positive topline results from a confirmatory clinical study for AVT05, a proposed biosimilar for Simponi and Simponi Aria (golimumab)." https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm

### Jul 2024: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-03-27, last confirmed 2025-05-27.
- SEC Form 10-K (accession 0001628280-25-015052): "In July 2024, the Company announced positive topline results from a confirmatory patient study for AVT03." https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-003438): "In July 2024 , the Company announced positive topline results from this study, which met its primary endpoints ." https://www.sec.gov/Archives/edgar/data/1898416/000117184325003438/exh_992.htm
- SEC Form 10-K (accession 0001628280-25-015052): "In July 2024, we announced positive topline results from this study, which met its primary endpoints." https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm

### Nov 2024: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2025-06-06, last confirmed 2026-05-29.
- SEC Form 10-K (accession 0001575872-26-000381): "In November 2024, the U.S. FDA issued a complete response letter ("CRL") with additional queries in reference to the ongoing resolution of observations arising from the October 2023 inspection, as well as certain aspects pertaining to our biologics license application ("BLA") for a biosimilar rituximab." https://www.sec.gov/Archives/edgar/data/1135951/000157587226000381/rdy0899_20f.htm
- SEC Form 10-K (accession 0001575872-25-000393): "In November 2024, the U.S. FDA issued a complete response letter ("CRL") with additional queries in reference to the ongoing resolution of observations arising from the October 2023 inspection, as well as certain aspects pertaining to our biologics license application ("BLA") for a biosimilar rituximab." https://www.sec.gov/Archives/edgar/data/1135951/000157587225000393/rdy-20250331.htm

### Jan 2025: NDA/BLA acceptance

- Status: completed. Date confidence: month. Indication: with inflammatory conditions.
- First seen 2025-05-27, last confirmed 2026-03-31.
- SEC Form 10-K (accession 0001898416-26-000004): "In January 2025, the FDA accepted our BLA for AVT05 as a proposed biosimilar to Simponi / Simponi Aria (golimumab) for the treatment of patients with inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis." https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/alvo-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-003438): "In January 2025 , the Company announced that the FDA had accepted the BLA for AVT 03 , AVT 05 , and AVT 06 for review ." https://www.sec.gov/Archives/edgar/data/1898416/000117184325003438/exh_992.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-003438): "In January 2025 , the Company announced that the FDA had accepted its BLA for filing and the Company anticipate review to be completed in the fourth quarter of 2025 ." https://www.sec.gov/Archives/edgar/data/1898416/000117184325003438/exh_992.htm

### February 18, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: eye disorders.
- First seen 2025-03-27, last confirmed 2026-03-31.
- SEC Form 10-K (accession 0001628280-25-015052): "In February 2025, the Company announced that the FDA has accepted for review a BLA for AVT06." https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm
- SEC Form 10-K (accession 0001628280-25-015052): "On 18 February 2025, the Company announced that the FDA has accepted for review a BLA for AVT06, Alvotech's proposed biosimilar to Eylea (aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness." https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm
- SEC Form 10-K (accession 0001898416-26-000004): "In February 2025, the FDA accepted our BLA for AVT06 as a proposed biosimilar to Eylea (aflibercept) for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema, and diabetic retinopathy." https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/alvo-20251231.htm

### March 18, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: osteoporosis in women.
- First seen 2025-03-27, last confirmed 2026-03-31.
- SEC Form 10-K (accession 0001628280-25-015052): "On 18 March 2025, the Company announced the FDA acceptance of BLA for AVT03, a proposed biosimilar to Prolia and Xgeva (denosumab)." https://www.sec.gov/Archives/edgar/data/1898416/000162828025015052/alvo-20241231.htm
- SEC Form 10-K (accession 0001898416-26-000004): "In March 2025, the FDA accepted our BLA for AVT03 as a proposed biosimilar to Prolia (denosumab) for the treatment of osteoporosis in women after menopause who are at high risk for bone fracture and Xgeva (denosumab) a prescription biologic medicine used to prevent fracture, spinal cord compression, or the need for radiation or surgery to bone in patients with multiple myeloma and in patients with bone metastases from solid tumors." https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/alvo-20251231.htm

### Apr 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-06-06, last confirmed 2025-06-06.
- SEC Form 10-K (accession 0001575872-25-000393): "While we submitted a deficiency response letter for the CRL in April 2025, and resubmitted our BLA, there is no certainty on timelines as to when the U.S. FDA will ultimately approve our resubmitted BLA, or guaranty of such approval, and we could experience further delays relating to the development of the biosimilar product." https://www.sec.gov/Archives/edgar/data/1135951/000157587225000393/rdy-20250331.htm

### February 5, 2026: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2026-03-31, last confirmed 2026-03-31.
- SEC Form 10-K (accession 0001898416-26-000004): "On 5 February 2026, the Group announced positive top-line results from its pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio (vedolizumab)." https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/alvo-20251231.htm

## Same indication

- [PAVBLU® (aflibercept)](https://sec-api.dev/pdufa/aflibercept) (REGN)
- [Prolia® (denosumab)](https://sec-api.dev/pdufa/denosumab) (AMGN)
- [Eylea® (eylea)](https://sec-api.dev/pdufa/eylea) (REGN)
- [Aria® (golimumab)](https://sec-api.dev/pdufa/golimumab) (JNJ)
- [Lucentis® (ranibizumab)](https://sec-api.dev/pdufa/ranibizumab) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/biosimilar.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Biosimilar PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/biosimilar

```bibtex
@misc{secapidev_pdufa_biosimilar_20261116,
  title        = {Biosimilar PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/biosimilar}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_biosimilar_20261116","title":"Biosimilar PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/biosimilar","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
